Canadian cannabis giant Tilray, Inc. TLRY is scheduled to report its quarterly earnings on July 28th, before the market opens. Year-to-date, the stock is up 35.12%.
Tilray, based in New York and Leamington, Ontario, recently confirmed that another independent proxy advisory firm is recommending that shareholders back all of the company’s proposals at a special meeting scheduled for July 29. This time, the proxy advisory services company Glass Lewis also advised shareholders to vote in favor of the company’s dilution as well as other proposals.
The Analyst
Cantor Fitzgerald’s Pablo Zuanic kept an ‘Overweight’ rating on Tilray's stock but lowered the price target to $19 from $24.
The Thesis
The combined company’s May quarter report will include a full quarter of the old Aphria (through May) and one month of the old Tilray as well as Pro-forma numbers by division for the 12-month period ending May, wrote Zuanic in a Tuesday analyst note.
See also: How to Buy Tilray Here (ACB) Stock
“So, we will not be able to judge cannabis sales trends (what really matters, in our view).”
Tilray is expected to report a flat quarter with share loss coming from Aphria and gains from Tilray, noted Zuanic, explaining that lowering the price target is due to the recent sectorial derating.
The analyst expressed concern that the headline consensus numbers are not accurate “as it is a blended comparison of apples to oranges.” The FactSet consensus projected $193.3 million sales for the quarter, which, according to Zuanic, “does not seem right” since there was no sequential growth. Without it, the numbers should be around $140 million.
“Our pro forma numbers for the May quarter are $175Mn (or about 5% down sequentially).”
The analyst further listed several possible catalysts from the financial report:
- Domestic recreational outlook;
- U.S. plans;
- Overseas growth commentary;
- Dealing with the convertible debt.
The Price Action
Tilray’s shares were trading 6.68% lower at $12.79 per share at the time of writing.
Photo: Courtesy of Esteban Lopez on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.